Loading, Please Wait...
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2018 and reported on recent corporate developments. Corium's fiscal year ends on September 30.
"We remain on track to file our Corplex Donepezil NDA in the first quarter of 2019 and look forward to delivering an important new treatment option for patients with Alzheimer’s disease and their caregivers,” said Peter D. Staple, President and Chief Executive Officer of Corium. “We are executing on our strategic plan to leverage our Corplex technology to expand our proprietary pipeline with the development of additional “first-in-patch” transdermal therapeutics. We’ve identified several promising candidates in therapeutic areas with significant unmet needs that, based on our initial formulation and feasibility work, meet our technical and commercial criteria for further development.”
Financial Results for the Quarter and Nine Months Ended June 30, 2018
Corium reported total revenues of $7.7 million for the third quarter of fiscal 2018, compared with $8.1 million for the same period of fiscal 2017, and reported total revenues of $27.0 million for the nine-month period ended June 30, 2018, compared with $22.4 million for the same period in fiscal 2017. Product revenues were essentially unchanged for the third quarter of fiscal 2018, compared to the same period in fiscal 2017, primarily as a result of a decrease in Clonidine TDS revenues, offset by an increase in revenues from Crest Whitestrips and Fentanyl TDS. Product revenues increased for the nine-month period ended June 30, 2018, compared to the same period in fiscal 2017, as revenues from Procter & Gamble increased, reflecting strong demand for the Crest Whitestrips products. Contract research and development (R&D) revenues decreased for the third quarter of fiscal 2018, compared to the same period in fiscal 2017, as a result of reduced development work for Agile’s Twirla® product and several other partner programs, partially offset by higher revenues from activities associated with implementing the new production capacity for P&G. Contract R&D revenues increased for the nine-month period ended June 30, 2018, compared to the same period in fiscal 2017, due to increased support for Agile’s regulatory activities, increased product development for Mayne, and the implementation of the new production capacity for P&G.
Total R&D expenses were $10.6 million in the third quarter of fiscal 2018, compared with $12.1 million in the same period of fiscal 2017, and were $39.7 million for the nine-month period ended June 30, 2018, compared with $30.5 million in the same period in fiscal 2017. The decrease in total R&D expenses for the third quarter reflects the lower level of clinical activity for Corplex Donepezil during this period. The increase in total R&D expenses for the nine-month period was driven by Corium’s investment in bioequivalence trials for Corplex Donepezil, as well as the ancillary clinical trials required to support the NDA filing for the product, in addition to increased expenses associated with feasibility programs for new products.
General and administrative (G&A) expenses were $3.3 million for both the third quarter of fiscal 2018 and for the same period of fiscal 2017, and were $10.7 million for the nine-month period ended June 30, 2018, compared with $9.3 million in the same period in fiscal 2017. The increase in G&A expenses for the nine months was primarily driven by higher one-time legal and outside services costs in the second quarter, as well as higher stock-based compensation costs.
Corium reported a net loss of $12.4 million for the third quarter of fiscal 2018, or $0.34 per share, compared with a net loss of $13.4 million, or $0.43 per share, in the same period of fiscal 2017. For the nine-month period ended June 30, 2018, the net loss was $43.7 million, or $1.21 per share, compared with a net loss of $34.9 million, or $1.30 per share, for the same period in fiscal 2017. As of June 30, 2018, there were 36,244,074 shares of Corium common stock outstanding.
Cash and cash equivalents as of June 30, 2018 were $82.5 million.
Conference Call and Webcast Details
Corium will host a conference call today at 5:00 p.m. ET (2:00 p.m. PT) to discuss the financial results for the third fiscal quarter and the nine months ended June 30, 2018. Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 4192359. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. The webcast will be archived on the Corium website for two weeks following the presentation.
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. For further information, please visit www.coriumintl.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, market and growth opportunities and demand for our commercial products, financial and operating performance, product pipeline, intellectual property rights and portfolio, clinical trial and regulatory timing and plans, regulatory pathways for our development programs, the achievement of clinical and commercial milestones, and the advancement of our technologies as well as our proprietary, co-developed and partnered products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its results are detailed in Corium's Annual Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission (SEC) on May 15, 2018, and other reports as filed from time to time with the SEC. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial or operating performance, which speak only as of the date they are made. Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Corplex™ and MicroCor® are trademarks of Corium International, Inc.
Aricept® is a registered trademark of Eisai R&D Management Co, Ltd.
Crest® Whitestrips is a registered trademark of The Procter & Gamble Company.
Twirla® is a registered trademark of Agile Therapeutics, Inc.
Investor and Media Contact:
Susan M. Pietropaolo
CORIUM INTERNATIONAL, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
|Three Months Ended June 30,||Nine Months Ended June 30,|
|Contract research and development revenues||1,529||1,936||7,813||5,320|
|Costs and operating expenses:|
|Cost of product revenues||3,507||3,935||10,806||10,892|
|Cost of contract research and development revenues||2,339||2,977||9,238||7,891|
|Research and development expenses||8,305||9,122||30,511||22,650|
|General and administrative expenses||3,325||3,284||10,728||9,288|
|Amortization of intangible assets||183||159||541||514|
|Loss on disposal of equipment||4||6||4||6|
|Total costs and operating expenses||17,663||19,483||61,828||51,241|
|Loss from operations||(9,993||)||(11,374||)||(34,783||)||(28,819||)|
|Loss on extinguishment of long-term debt||—||—||(2,258||)||—|
|Loss before income taxes||(12,391||)||(13,384||)||(43,687||)||(34,848||)|
|Income tax expense||—||—||2||2|
|Net loss and comprehensive loss||$||(12,391||)||$||(13,384||)||$||(43,689||)||$||(34,850||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.34||)||$||(0.43||)||$||(1.21||)||$||(1.30||)|
|Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted||36,214,740||31,457,702||36,144,746||26,784,678|
CORIUM INTERNATIONAL, INC.
CONDENSED BALANCE SHEETS
(In thousands, except share and per share data)
|As of June 30,||As of September 30,|
|Cash and cash equivalents||$||82,523||$||57,466|
|Unbilled accounts receivable||228||169|
|Prepaid expenses and other current assets||924||982|
|Total current assets||88,917||65,558|
|Property and equipment, net||15,810||12,176|
|Intangible assets, net||7,404||7,117|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other current liabilities||6,860||6,411|
|Long-term debt, current portion||49||13,172|
|Recall liability, current portion||119||114|
|Deferred contract revenues, current portion||137||626|
|Total current liabilities||11,684||24,301|
|Convertible notes, net||70,021||—|
|Long-term debt, net of current portion||337||39,027|
|Recall liability, net of current portion||1,697||1,811|
|Deferred contract revenues, net of current portion||3,500||3,500|
|Commitments and contingencies|
|Additional paid-in capital||283,826||231,457|
|Total stockholders’ equity||24,892||16,212|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||112,131||$||84,851|